European Commission Approval Gives Blood Cancer Patients a New Cell Therapy Option
Zemcelpro, a cord blood-sourced cell therapy developed by startup ExCellThera, received conditional marketing authorization in…
European Commission Approval Gives Blood Cancer Patients a New Cell Therapy Option
Zemcelpro, a cord blood-sourced cell therapy developed by startup ExCellThera, received conditional marketing authorization in Europe as a treatment for blood cancer patients who can’t find a matched donor. It’s the first cell therapy approved in Europe for this group of patients. The post European Commission Approval Gives Blood Cancer Patients a New Cell Therapy…
CDC Director Ousted After Less Than a Month on the Job
Susan Monarez has left her role as CDC director after less than a month — the shortest tenure in the agency’s history — following reported clashes with HHS Secretary Robert F. Kennedy Jr. over vaccine policy. This news comes amid a period of turmoil at the CDC, including a recent deadly shooting at its headquarters….
Do people like to daydream?
Not really. At least according a study by Wilson et al. 2025 in Science. In 11 studies, we found that participants typically did not enjoy spending 6 to 15 minutes in a room by themselves with nothing to do but think, that they enjoyed doing mundane external activities much more, and that many preferred to…
Bringing Clinical Data Management to the Cloud
Moving clinical data management to cloud platforms can carry myriad benefits for healthcare organizations. The post Bringing Clinical Data Management to the Cloud appeared first on MedCity News.
CMS doesn’t consider QALYs – What’s a health economist to do?
That is the title of my article out today in The Evidence Base. Here is an excerpt: The Centers for Medicare and Medicaid Services (CMS) are now setting drug prices under the Medicare Drug Price Negotiation program. Unlike other health technology assessment (HTA) bodies worldwide, however, CMS will not consider quality-adjusted life years (QALYs) when setting drug…
How Can Hospital-at-Home Grow Outside the Nation’s Biggest Health Systems?
The path to a sustainable HaH program looks different for regional systems. A smaller, more focused program, designed around their unique needs, can deliver strong clinical and operational value. The post How Can Hospital-at-Home Grow Outside the Nation’s Biggest Health Systems? appeared first on MedCity News.
The Role of RWD in Revolutionizing Clinical Trial Design
[Sponsored] Using RWD to understand SDOH factors faced by patients with non-small cell lung cancer paves the way for improving health equity and more effective treatments for more people. The post The Role of RWD in Revolutionizing Clinical Trial Design appeared first on MedCity News.
We Should Write a Really Stern Letter
By KIM BELLARD On the heels of the disastrous floods in Texas, days away from the Hurricane Katrina twenty year anniversary, and with Hurricane Erin almost becoming another Hurricane Sandy, the dedicated employees at FEMA are worried. Very worried. They’ve got a President who repeatedly has called to dismantle the agency, a DHS Secretary who…
Duke Spinout Launches Platform to Unite Care and Clinical Research
Pluto Health launched an AI-driven digital hub that unifies fragmented health data, provides personalized care navigation and integrates clinical research opportunities to help close primary care access gaps. The platform aims to improve care coordination and make research participation more accessible, especially for patients without insurance or a regular primary care provider. The post Duke…
Regeneron’s RNA Med for Muscle Disease Meets Trial Goals; FDA Filing Planned for Next Year
Cemdisiran, a small interfering RNA drug that Regeneron Pharmaceuticals licensed from Alnylam Pharmaceuticals, met the goals of its pivotal test in generalized myasthenia gravis. The rare neuromuscular disease has several new therapies, but analysts see cemdisiran as having advantages over one particular class of drugs. The post Regeneron’s RNA Med for Muscle Disease Meets Trial…
